Discontinuation of Alprazolam after successful treatment of panic disorder: a naturalistic follow-up study by Abelson, James L. & Curtis, George C.
foumd of Anxiety Disoderr, Vol. 7. pp. 107-I 17. 1993 
Prinkd in the USA. All rights rsaved. 
0887-6185/93 WJO + .oO 
Copyri@~l 0 1993 Pagamon Prcs Ltd. 
Discontinuation of Alprazolam After 
Successful Treatment of Panic Disorder: 
A Naturalistic Follow-up Study 
JAMES L. ABELSON, M.D., PH.D., AND GEORGE C. CURTB, M.D. 
University of Michigan 
Abstract - Low rates of benzodiazepine discontinuation have been seen in long- 
term outcome studies of alprazolam-treated panic disorder. Discontinuation studies 
reveal high rates of relapse when alprazolam is stopped. Available data may lack rele- 
vance to clinical practice, however, because drug taper rates are often more rapid than 
those used in many clinical settings. In order to obtain naturalistic data on the long- 
term course of alprazolam treatment of panic, we obtained follow-up data on 18 of 20 
patients who had been enrolled one to two years earlier in a study of alprazolam 
effects on hypothalamic-pituitary-adrenal (HPA) axis functioning. The HPA protocol 
provided measures of symptom severity, biological markers, and short-term treatment 
response (12 weeks). Routine clinical care was then provided, with dosage adjust- 
ments dictated by individual clinical needs. The follow-up study repeated clinical 
measures at a mean of 21 months after initiation of treatment. AIprazolam was discon- 
tinued in 78% of patients. Relapse occurred in 36% of these. At follow-up, 61% were 
medication-free. Only 28% were on a benzodiazepine. The four patients remaining on 
alprazokrm were on reduced doses and had maintained clinical gains. HPA axis activi- 
ty did not predict dose or outcome. Factors related to successful alprazohun discontin- 
uation are discussed. 
Alprazolam is now an approved treatment for panic disorder, but discontin- 
uation difficulties raise concerns about the long-term course of alprazolam- 
treated patients. Complications of alprazolam discontinuation include the fol- 
lowing: (a) relapse, which is the recurrence of the anxiety symptoms for which 
treatment was originally sought; (b) rebound, which is relapse in which symp- 
tom intensity exceeds pretreatment baselines; and (c) withdrawal, which is the 
occurrence of specific symptoms associated with benzodiazepine discontinua- 
tion that were not present prior to treatment (Pecknold et al., 1988). 
Discontinuation studies have demonstrated high rates of all three phenomena 
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(e.g., relapse rates of > 74%) during alprazolam taper (Fyer et al., 1987; 
Noyes et al., 1991). Data from discontinuation studies may lack relevance to 
clinical practice, however, because drug taper rates are dictated by protocol 
and are extremely rapid by clinical standards (0.25-0.5 mg reductions every 
three days). Slower rates and individualized taper programs may result in less 
relapse, rebound, and/or withdrawal. 
Results of long-term outcome studies may be more relevant to clinical 
experience, but the limited data available from such studies also show low 
rates of successful discontinuation of the high-potency benzodiazepines used 
to treat panic disorder. In panic patients initially treated with alprazolam, fol- 
low-up at 1 to 2.5 years showed benzodiazepine discontinuation in less than 
50% (Nagy et al., 1989; Pecknold, 1990; Rickels, 1990). Follow-up of patients 
begun on alprazolam or clonazepam in a controlled treatment trial showed 
73% still on a benzodiazepine and 78% still on medication 1.5 years later 
(Pollack et al., 1991). These data may suggest to some that obtaining drug-free 
remission of panic disorder is an unlikely outcome when treatment is initiated 
with benzodiazepines. In light of evidence from long-term follow-up of cogni- 
tive/behaviorally treated panic, which shows up to 81% of patients to be drug- 
free and panic-free at two years (Barlow, 1990), the benzodiazepine outcome 
data could be used to argue against the use of high-potency benzodiazepines 
in the treatment of panic. However, such conclusions may be unwarrranted 
because the few available long-term outcome studies of benzodiazepine-treat- 
ed panic were not designed to obtain drug-free remissions, and in some cases 
were specifically examining the results of long-term continuation of medica- 
tion. Study goals and the availability of alternative treatment modalities are 
likely to significantly effect the rate of benzodiazepine discontinuation. If 
high-potency benzodiazepines have an appropriate place in our anti-panic 
armamentarium, then we need additional information on how successfully 
they can be discontinued. Higher rates of discontinuation should be possible 
when these medications are utilized in a setting in which the goal of treatment 
is to obtain drug-free, impairment-free, minimal symptom outcomes, and in 
which the intensity and modality of treatment can be flexibly altered in efforts 
to reach that goal. Documentation of reduced relapse rates and improved dis- 
continuation rates would support the appropriate utilization of alprazolam in 
some cases. Clinical guidelines that can facilitate discontinuation of alprazo- 
lam would be especially helpful. 
We collected naturalistic data on the long-term course of alprazolam 
treatment of panic by conducting a follow-up study of patients who had 
been enrolled one to two years earlier in a study of alprazolam effects on 
hypothalamic-pituitary-adrenal (HPA) axis functioning. Entry into the fol- 
low-up study via the biological protocol insured that the patients were sub- 
jected to rigorous screening, standardized entry into treatment, and detailed 
clinical monitoring. It also facilitated examination of biological and clinical 
predictors of outcome. The taper and discontinuation phase was conducted 
naturalistically by clinicians skilled in the use of other medications and 
cognitive/behavioral techniques. Treatment goals included eventual discon- 
tinuation of medication and maintenance of a non-impaired, minimal symp- 
tom state. 
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METHOD 
Twenty patients with DSM-III-R defined panic disorder participated in the 
HPA study, which was begun in October, 1988. All were medically healthy, 
drug-free, and had no current or primary depression. They were diagnosed 
using a Structured Clinical Interview for DSM-III-R (KID-UP) (Spitzer & 
Williams, 1986). Assessment of HPA axis function included 24-hour corti- 
cotropin (ACTH) profiles (sampling every 15 minutes) and a corticotropin- 
releasing hormone (CRH) stimulation test (Roy-Byrne et al., 1986). Patients 
then entered a flexible-dose, open-label alprazolam protocol, beginning at a 
dose of 0.5 mg tid and advancing slowly until panic attacks were controlled. 
Patients were monitored weekly, using the same instruments used in the 
Cross-National Collaborative Panic Study (Ballenger et al., 1988). 
After 12 weeks of treatment, patients had repeat HPA axis assessment. They 
then transferred from the protocol to routine clinical care in which individual- 
ized treatment plans were developed. Alprazolam dose was adjusted as neces- 
sary to obtain or maintain full remission of panic symptoms. Adjunctive cog- 
nitive-behavioral therapy (CBT) was provided if significant panic or avoid- 
ance remained. New depressive episodes were treated with antidepressant 
medication. After one to three months of stable remission, alprazolam dose 
reductions were initiated. The treatment contract included the goal of eventual 
medication discontinuation, but discontinuation was not emphasized when 
dose reductions were initiated. These were presented as collaborative searches 
for the minimal dose needed to maintain remission. Patients retained control 
over the pace of reductions, but were cautioned to go no faster than 0.25 mg 
every two weeks. Symptoms appearing during taper were used as opportuni- 
ties for in vivo desensitization to somatic cues and as a context for practicing 
cognitive coping techniques. If relapse occurred, antidepressants or additional 
behavioral treatments were utilized. 
In the fall of 1990 patients were re-interviewed. Treatment and illness 
course were obtained and clinical rating scales were repeated. Eighteen of 
the original twenty patients were interviewed. Two had left the state and 
could not be reached. Sixteen patients had received all follow-up care 
through our clinic. Nine were treated by the HPA study psychiatrist (JLA) 
with medication management and informal CBT as needed to manage re- 
emergent symptoms. Two received similar treatment from a nurse clinician 
with four years of experience in providing multi-modal treatment to patients 
with anxiety disorders. Five were treated by the nurse clinician with medica- 
tion management and formal CBT in either a structured group or individual 
setting. Two patients had transferred their care to psychiatrists closer to their 
homes. Variables used in data analyses are listed and described in Table 1. 
Descriptions of the clinical instruments can be found in Ballenger et al. 
(1988). Additional HPA axis variables were also analyzed, including 24- 
hour secretory pulse frequency and amplitude and net ACTH response to 
CRH, these same measures after 12 weeks of treatment, and the change in 
each HPA axis measure from before to during treatment. The results were 
identical regardless of measure used so, to conserve space, only the two 
variables listed in Table 1 are reported. 
110 J. L. ABELSON AND G. C. CURTIS 
TABLE 1 




Total score on the Hamilton Anxiety Rating Scale. 
Sum of avoidance scores on the 6 agoraphobia items of the 
Marks-Sheehan Phobia Scale. 
Total disability 
Panic attacks per week 
Sum of the subscale scores on the Sheehan Disability Scale. 
Average number of attacks per week over the prior month, 
from the Panic Attack and Anticipatory Anxiety Scale. 
Composite Sxs Sum of the scores on the above 4 clinical measures. 
Duration of taper Months until full discontinuation, counting from the first 
reduction of alprazolam dose after completion of the HPA 
protocol and achievement of stable remission. Duration was 
adjusted for those patients still on alprazolam by adding the 
additional time required to discontinue if tapered at the 
maximal allowable rate (0.25 mg every 2 weeks). 
Duration on drug 
Relapse 
ACTH-24h AUC 
Peak resp to CRH 
Months from initiation of treatment with alprazolam to 
discontinuation, adjusted as above for those still on drug. 
Recurrence of symptoms again meeting DSM-III-R criteria 
for the diagnosis of panic disorder. 
Area under the 24 hour ACTH curve, prior to treatment, 
calculated by trapezoidal approximation. 
Peak ACTH level after CRH infusion minus the mean of the 
3 samples prior to infusion (prior to initiation of treatment). 
RESULTS 
Of the 18 patients completing the follow-up study, 10 were female and 8 
male. Their mean (+ SD) age al entry was 30.2 (+ 5.8) years. They had been ill 
6.1 (& 8.3) years. They were having 3.5 (+ 2.7) panic attacks per week; and 
their mean Hamilton Anxiety Scale score was 15.3 (& 7.X). Twelve had mild 
to moderate agoraphobia and six were not agoraphobic (by SCID). Nine had 
some history of other DSM-III-R Axis I diagnoses. Four had current or past 
generalized anxiety disorder. Two had histories of major depressive episodes 
and two of substance abuse (all in remission for > 6 months). There was one 
patient with social phobia and one with a simple phobia (heights). 
Outcome 
After 12 weeks of treatment, patients were taking a mean alprazolam dose 
of 4.1 mg/day. Substantial and significant clinical improvement had been 
obtained (see Table 2). The follow-up study repeated clinical measures 11 to 
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TABLE 2 
CLWICALSTATUSBFZFORETREATMENT,AFER 12 WEEKS ON ALPRAZOLAM,ANDATFOLLOW-UP 
(MEAN~SD) 
Pretreatment On drug Follow-up 








15.3 (k7.8) 6.4 (fi.7) ** 7.2 (f5.7) * 5.3 (f4.3) 
7.1 (f5.5) 3.0 (k3.7) * 2.1 (f3.5) ** 2.2 (k3.9) 
16.2 (i8.5) 8.3 (f7.3) ** 5.4 (24.0) ** 4.2 (k2.6) t 
3.5 (f2.7) 0.8 (k1.5) ** 0.6 (fl.9) ** 0.2 (M.6) 
** significantly less than pmtreatment, p < ,001 
* significantly less than pretreatment, p < ,005 
t significantly less than on drug, p < .05 (all analyses are paired t-tests) 
26 months after initiation of treatment (mean = 21 months). Patients were 
treated with alprazolam for 4.5 to > 22 months (mean adjusted duration = 11.6 
months). Drug tapers lasted from 1 to > 18 months (mean adjusted duration = 
7.7 months). Alprazolam was discontinued in 78% of patients. Relapse 
occurred in 36% of these, an average of 6.4 months after drug discontinuation 
(range = 1 to 18 months). At follow-up, 6 1% of patients were medication-free. 
Only 28% were on a benzodiazepine. No one who discontinued alprazolam 
restarted it. One patient was switched from alprazolam to clonazepam. All 
patients remaining on alprazolam (n = 4) were on substantially reduced doses. 
These four patients had reduced their alprazolam dose from a mean of 5.0 
mg/day at 12 weeks to 2.1 mg/day at follow-up. At follow-up they had been 
on drug for 18.8 months and had been tapering for 13.3 months. They had 
maintained their clinical gains (their mean composite symptom score at 12 
weeks was 13.0 and at follow-up was 12.7). The total group remained signifi- 
cantly improved at follow-up, compared to pre-treatment, despite the presence 
of five relapsers; and non-relapsing patients showed significant additional 
reduction in disability between 12 weeks and follow-up (Table 2). 
Relapse was defined as the recurrence of symptoms again meeting DSM- 
III-R criteria for panic disorder. All patients who relapsed were medication- 
free at the time of relapse. Two relapsers were treated with an antidepressant 
(fluoxetine). One of these had a major depressive episode successully treated 
with nortriptyline during the follow-up period, but was med-free and not 
depressed at time of panic relapse; the other had significant dysphoric mood 
associated with her relapse. Both responded well to fluoxetine and CBT. The 
other three relapsers, one of whom also had a major depressive episode associ- 
ated with her relapse, did not require resumption of medication and were suc- 
cessfully managed with CBT alone. One patient who did not have a relapse of 
her panic disorder also experienced a major depressive episode during the fol- 
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low-up period, and was successfully treated with fluoxetine. None of the three 
patients (17%) who developed major depressive episodes had a prior history 
of depression. 
Predictors of Outcome 
In order to explore outcome predictors we divided the patients into two 
groups: those who had achieved the goal of medication discontinuation with- 
out relapse (“Med-free/Remitted”) and those who had not (“On-meds or 
Relapsed”), and compared these groups on clinical, biological, and treatment 
variables (see Table 3). The “Med-free/Remitted” group was doing quite well 
at follow-up - they were nearly panic-free (one of them had a single panic 
attack in the month prior to the follow-up interview) and had an extremely low 
mean HAM-A score (see Table 3). The “On-meds or Relapsed” group was 
significantly more symptomatic, but even their mean HAM-A score and panic 
attack frequency (Table 3) were low relative to those reported in other out- 
come studies (Nagy et al., 1989; Barlow, 1990; Pecknold et al., 1988). Though 
they differed in clinical status at follow-up, the groups did not differ signifi- 
TABLE 3 
COMPARISON OF THE Two O~JXOME GROUPS ON CLINICAL, DRUG, AND HPA VARIABLES 
“Med.free/Remitted” “On-meds or Relapsed” 
(n = 7) (It= 11) 
t * 
P 
Composite Sxs (Pretreatment) 35.0 (f19.7) 46.5 (i-21.8) 1.14 
Composite Sxs (12 wks) 18.4 (k16.1) 18.7 (f13.3) .04 
Composite Sxs (follow-up) R.8 (+ 7.9) 18.3 (f10.6) 2.03 
IIAM-A (follow-up) 3.7 (* 2.9) Y.6(+6.1) 2.36 
Dtrabdity (follow-up) 2.7 (? 1.5) 7.2(?4.1) 2.72 
P:tnic attacks/wk (follow-up) 0.1 (* 0.2) 1.87 
ACTH-24h AUC (pg/ml*min) 23464 (+6003) .37 
Pe;ik resp to CRH (pgiml) 36.9 (k16.6) 
0.9 (& 1.1) 
21858 (110385) 
45.9 (f30.1) 
5.0 (* 1.8) 
.72 










Duration of taper (mos.) 3.2 (k 1.9) 10.4 (* 6.3) 2.90 
Duratton on drug (mos.) 6.3 (* 1.8) 15.0 (i 7.2) 3.11 
Age at ttme of study (yrs.) 28 (* 7.4) 31.6(14.2) 1.34 
Age at panic onset (yrs.) 1x.3 (& 6.6) 28 (* 4.0) 3.4, 
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cantly in clinical status prior to treatment. The “On-meds or Relapsed” group 
had higher scores on the composite symptom index (Table 3) and each of the 
clinical scales making up this index, but none of these group differences 
reached significance. After 12 weeks of treatment, the two groups had nearly 
identical scores on all of the clinical variables. The groups were nearly identi- 
cal on all measures of HPA activity, both before treatment and after 12 weeks 
on medication. The “On-meds or Relapsed” group was on a higher dose of 
alprazolam at 12 weeks and tapered more slowly, remaining on drug signifi- 
cantly longer than the “Med-free/Remitted” group. The “On-meds or 
Relapsed” group also had a greater age of onset of their panic disorder, but did 
not differ in age at time of study. 
Correlational analyses confirmed the relationship between alprazolam dose 
and outcome, with significant positive correlations between dose at 12 weeks 
and follow-up HAM-A score (r = .74, p = .0007), panic attack frequency 
(r = .69, p = .002), and disability (r = .71, p = .0009). Dose was not related to 
clinical severity prior to treatment and was not related to HPA axis variables 
(r c .37, p > .12 for all variables). 
Chi-square analyses revealed no relationship between outcome and the 
presence or absence (current or past) of other Axis I disorders (X2(1) = .23, 
p = .63). “Med-free/Remitted” status was related at a trend level to the 
absence of SCID-diagnosed agoraphobia (X2(1) = 2.92, p = .09). Sixty-seven 
percent of six non-agoraphobics were medication-free and non-relapsed at fol- 
low-up, compared to 25% of the 12 agoraphobics. 
Difficulty in discontinuing alprazolam (duration of taper) was not related to 
any measure of clinical, drug, or HPA status. Age of onset of panic disorder 
was related to duration of taper (r = .55, p = .02). 
DISCUSSION 
Twenty-one months after initiation of alprazolam treatment, 72% of our 
patients had discontinued use of benzodiazepines. In other published studies, 
only 27%-47% of patients were off high-potency benzodiazepines at 12 to 30 
month follow-up (see Table 4). Despite our high rate of benzodiazepine dis- 
continuation, our relapse rate was similar to that seen following cessation of 
non-benzodiazepine drug treatment of panic disorder (Mavissakalian, 1982; 
Zitrin et al., 1980); and levels of residual symptomatology in non-relapsing 
medication discontinuers were quite low. Though it is difficult to compare lev- 
els of residual symptomatology across studies, our “Med-free/Remitted” 
group was doing well at follow-up by any available standards of panic disor- 
der outcome research (0.1 panic attacks/week, six of the seven patients panic- 
free, and a mean HAM-A of 3.7). Even the total patient group (including the 
five relapsers) had a fairly low mean HAM-A score and panic attack rate at 
follow-up. The following factors may have contributed to successful benzodi- 
azepine discontinuation: (a) the use of cognitive-behavioral techniques to treat 
residual and recurrent symptoms; (b) the use of antidepressant medications 
when a return to drug treatment was necessary; (c) an explicit goal, agreed 
upon between patient and clinician, to work towards achievement of drug- 
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TABLE4 
LONG-TF.RM Ourco~~ SWDIE~ OF HIGH-P~NCY BENZODIAZEPWE TREAIME~ OF PAIIENTS wrtx 
PANIC DISORDER 
stopped relapse duration On 
Author n benzodiazepine in: rate (mos.) On drug benzodiazepine 
Nagy et al ‘89 60 alprazolam ? ? 30 70% 70% 
Pecknold ‘90 142 alprazolam 66.9% 29% ? 52.8% 52.8% 
Rick& ‘90 27 alprazolam 70% 37% 14 56% 56% 
Pollack et al ‘86 50 clonazepam 42% ? I2 58% 54% 
Pollack et al ‘91 59 both ? ? 18 78% 73% 
free, impairment-free, minimal-symptom outcomes; and (d) an approach to 
that goal that emphasized slow taper rates, patient control, and minimization 
of symptoms rather than focussing on discontinuation. 
Our sense of success is tempered by the fact that at follow-up, 11 of 18 
patients had not achieved the goal of medication-free remission. Nearly two 
years after coming to the clinic, the majority of patients remained in need of 
ongoing treatment. This may reflect the chronic nature of panic disorder, or 
remaining inadequacies in our treatments. It is noteworthy, in light of recent 
recommendations for long-term medication continuation in panic disorder 
(Ballenger, 1992) that no relapses occurred while patients remained on medi- 
cation. However, it is also noteworthy that the majority of the relapses were 
successfully managed without a return to medication and none were refractory 
to treatment. Our patients appeared to do well compared to those in other fol- 
low-up studies of benzodiazepine-treated panic disorder (Nagy et al., 1989; 
Pecknold, 1990; Rickels, 1990; Pollack et al., 1991); but they did not do as 
well as patients in follow-up studies of CBT-treated panic (Barlow, 1990). 
Utilization of CBT may have improved our drug discontinuation rate and CBT 
alone may produce even better results; but it is risky to compare outcomes 
across studies done in different centers, utilizing varied methodologies and per- 
haps differing patient populations. Differences in initial symptom severity are 
particularly relevant, are difficult to control across studies, and may confound 
attempts to compare our outcomes to those of others. Though initial symptom 
severity did not predict outcome within our study, a relationship might have 
emerged with a larger sample. Our impression from this naturalistic study that 
our approach to alprazolam discontinuation facilitated improved long-term out- 
comes can only be definitively tested in a large-scale controlled trial. 
Although our study is not directly comparable to benzodiazepine discontin- 
uation studies (which use structured taper protocols to examine the immediate 
effects of discontinuation), we believe that our patients experienced consider- 
ably less subjective distress during taper than those patients described in the 
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discontinuation literature. Many patients tapering alprazolam in structured 
protocols report that during the taper their anxiety symptoms became worse or 
much worse than they had been prior to treatment (Noyes et al., 1991). 
Published protocols, however, use rapid dose reduction schedules (2 0.5 mg 
every three days), and authors have hypothesized that slower schedules would 
result in less distress (Noyes et al., 1991). Our patients did report significant 
distress associated with dose reductions, especially in the first one to five days 
after each reduction, but they were taught to cognitively block the develop- 
ment of this distress into full-blown panic attacks by properly attributing them 
to the dose reduction. They were encouraged to use their distress as an oppor- 
tunity to begin to desensitize themselves to anxiety-associated somatic cues. 
Many patients also reported that their ability to control the timing of dose 
reductions, so they could most comfortably fit the period of increased distress 
into their daily schedules, made it easier to move forward with further reduc- 
tions. The fact that the four patients who were in the midst of drug tapers at 
the time of follow-up were experiencing no increase in symptoms above their 
pre-taper, remitted states supports the hypothesis that slower, individualized 
taper programs do not lead to the substantial increase in symptoms and subjec- 
tive distress seen with structured taper protocols. 
We were able to identify only two factors that predicted better outcome: (a) 
a lower dose of alprazolam after 12 weeks of treatment; and (b) a lower age of 
onset of the disorder. The absence of agoraphobia may also predict better out- 
come. The link between dose and outcome could be partly due to the way we 
dichotomized outcome and included patients still on alprazolam at follow-up 
in the “On-meds or Relapsed” group. Higher doses at entry into follow-up 
might be expected to be linked to longer duration of tapers and increased like- 
lihood of remaining on drug at follow-up. However, the direct correlation 
between dose at 12 weeks and duration of taper was not significant, whereas 
dose at 12 weeks was highly correlated with clinical status at 21 months. This 
suggests that those patients who required higher doses of alprazolam to initial- 
ly control their symptoms did have poorer clinical outcomes in the long run. 
Surprisingly, this was not a function of initial symptom severity, which was 
not related to clinical outcome or alprazolam dose requirements. Factors such 
as panic subtypes (agoraphobic/nonagoraphobic), and Axis I and Axis II 
comorbidity have been linked to clinical status in long-term follow-up of 
panic patients (Noyes et al., 1990), and may mediate the link between dose 
required for initial control of symptoms and long-term outcome. Our data did 
support a link between agoraphobia and poorer outcome, but not between 
Axis I comorbidity and outcome. However, our sample size may have been 
too small to detect this latter association. We have no data on Axis II diag- 
noses in our patients. Additional research will be needed to identify more 
clearly the factors that determine initial dose requirements and link this to 
long-term outcome. Clinically, the data suggest a need to attend to factors 
such as phobic avoidance and comorbidity, and to consider other treatment 
modalities before pushing alprazolam to upper-range dosage levels. 
Reasons for a link between an older age of onset of panic disorder and 
greater difficulty in discontinuing alprazolam are not immediately apparent. 
Though group differences in duration of illness were not significant, the 
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“poorer” outcome patients surprisingly had more recent onset of their disorder. 
This finding may be an anomaly of our small sample, and further research is 
needed to verify and explore this potential predictive factor. 
There is some prior evidence that increased HPA activity is associated with 
increased risk of relapse upon alprazolam discontinuation (Coryell et al., 
1989) and increased symptomatology and disability at long-term follow-up 
(Coryell et al., 1991). We were not able to verify a link between HPA axis 
activity and clinical status at follow-up, despite very detailed study of the 
HPA axis. 
We conclude that in the context of a comprehensive anxiety management 
program, alprazolam can be used effectively, without abuse or tolerance in the 
sense of a need for escalating doses, and with successful discontinuation with- 
out a rate of relapse in excess of that seen with other, drugs. Given the inher- 
ent limitations of a naturalistic study, more extensive conclusions cannot be 
drawn. However, we believe that alprazolam need not be excluded from our 
anti-panic armamentarium. Its most appropriate role remains to be defined, 
given the availability of other pharmacological and non-pharmacological 
treatments; but we believe that it can be most useful when rapid, efficient 
control of acute symptoms is needed. We believe that if alprazolam is not 
effective in its lower dose range (l-3 mg/day), clinicians should consider 
adding an antidepressant medication and/or utilizing cognitive-behavioral 
techniques before pushing the alprazolam to higher dose levels. A useful 
approach to tapering alprazolam after successful treatment is to initiate a col- 
laborative search for the minimal effective dose, allowing patients control 
over the taper rate, reducing no faster than 0.25 mg/2 weeks, treating symp- 
toms that occur during taper as opportunities for desensitization to somatic 
cues, and utilizing antidepressants and/or behavioral treatment for symptom 
recurrence. Long-term outcomes may be enhanced by the ability to apply 
multiple modalities flexibly, including cognitive/behavioral techniques. 
Explicit attention to “comorbid factors,” including environmental and 
intrapsychic issues as well as panic subtypes and other Axis I and Axis II 
diagnoses, may also facilitate improved long-term outcomes. Research is 
needed to help us better match our growing arsenal of treatment techniques to 
the specific needs of individual patients. 
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